期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 23, 期 3, 页码 215-225出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14728222.2019.1561871
关键词
Apelin; obesity; type 2 diabetes; energy metabolism; apelin/APJ system
资金
- SFD (Societe Francophone du Diabete - French Diabetes Society)
- INSERM
- French Midi-Pyr enees region APRTCN grant
Introduction: Apelin, a bioactive peptide, is the endogenous ligand of APJ, a G protein-coupled receptor which is widely expressed in peripheral tissues and in the central nervous system. The apelin/APJ system is involved in the regulation of various physiological functions and is a therapeutic target in different pathologies; the development of APJ agonists and antagonists has thus increased. Area covered: This review focuses on the in vitro and in vivo metabolic effects of apelin in physiological conditions and in the context of metabolic diseases. Expert opinion: In experimental models, novel APJ agonists are efficient in vivo, to treat metabolic diseases and associated complications. However, more clinical trials are necessary to determine whether molecules that target APJ could become an alternative therapeutic strategy in the treatment of metabolic diseases and associated complications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据